All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Article

Pharmaceutical Technology Europe

December 18, 2009

FDA recommended to continue work on postmarket safety issues

Author(s):

Angie Drakulich

The Government Accountability Organization (GAO) has recommended the FDA Commissioner to develop a comprehensive plan for transferring additional regulatory authorities from the Office of New Drugs (OND) to the Office of Surveillance and Epidemiology (OSE) to help address weaknesses in the agency?s oversight of postmarket drug safety.

The Government Accountability Organization (GAO) has recommended that the FDA Commissioner develop a comprehensive plan for transferring additional regulatory authorities from the Office of New Drugs (OND) to the Office of Surveillance and Epidemiology (OSE) to help address weaknesses in the agency’s oversight of postmarket drug safety. The plan should include timefames and steps to ensure resources are properly aligned, says a report from the GAO.

The GAO has made several recommendations regarding the FDA’s postmarketing work over the past few years, including a 2006 report that the agency better define the roles of the OND and OSE offices. In this new report, GAO examines what the FDA is doing to improve its decision-making regarding the safety of marketed drugs, its access to data on drug safety issues and its capacity to fulfil its postmarket drug safety workload.

Overall, the GAO notes that although the FDA is "beginning to address previously identified weaknesses in its oversight of postmarket drug safety issues…challenges remain." Some positive steps include the agency’s Safety First Initiative, which involves formalizing interactions between the OND and OSE, and providing the OSE with added responsibilities. To date, the FDA has transferred premarket review responsibility from the OND to OSE, and plans to transfer to additional postmarket responsibilities (for reviewing certain types of drug safety studies).

"The FDA is also revising its programme for resolving scientific disputes, but these changes have not increased its independence, as GAO recommended," explained a previous report.The FDA also plans to implement new systems in 2010 to improve the timeliness, quality and analysis of reports of adverse events associated with human drug use; to increase funding for contracts with private companies; and to continue developing the Sentinel System — a network of external data providers intended to enhance drug safety surveillance, among other efforts.

Because of the agency's huge workload, however, it has been difficult for the OND and OSE staff to meet their responsibilities in full, says the GAO report. An increase in staff is needed (perhaps double the staff for OSE by fiscal year 2011), says the GAO. In addition, the agency needs help fulfilling several committee vacancies to help in its decision-making.

www.gao.gov

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
 Benjamin McLeod and Sebastian Lykke Skafte Andersen go behind the headlines to examine the motivations behind recent M&A activity, tariff responses, and more.
Related Content
Advertisement
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 29th 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Sustainable Solutions for Biopharma
August 29th 2025

Drug Solutions Podcast: Sustainable Solutions for Biopharma

Patrick Lavery
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 29th 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
August 29th 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey
August 29th 2025

Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey

Christopher Cole
A hand is placing the final wooden block with a green certificate checkmark, symbolizing achievement, quality assurance and completion, against a plain pastel blue background. | Image credit: TimmyTimTim – stock.adobe.com
August 29th 2025

Continued Process Verification Is Critical in Pharmaceutical Manufacturing

Philip Hoersch
Related Content
Advertisement
New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s
August 29th 2025

New Year, Same Challenges: Pharma’s Ongoing Struggle with FDA 483s

Patrick Falvey Georgia Sloboda Sarah DeDonder Lauren Schoukroun-Barnes
Drug Solutions Podcast: Sustainable Solutions for Biopharma
August 29th 2025

Drug Solutions Podcast: Sustainable Solutions for Biopharma

Patrick Lavery
Lung with tuberculosis, long covid or asthma disease, cancer cells, virus and air pollution, no tobacco day, organ donation | Image Credit: © Berit Kessler - stock.adobe.com
August 29th 2025

Cereno Scientific’s PAH Treatment Gets FDA Fast Track Status

Patrick Lavery
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
August 29th 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey
August 29th 2025

Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey

Christopher Cole
A hand is placing the final wooden block with a green certificate checkmark, symbolizing achievement, quality assurance and completion, against a plain pastel blue background. | Image credit: TimmyTimTim – stock.adobe.com
August 29th 2025

Continued Process Verification Is Critical in Pharmaceutical Manufacturing

Philip Hoersch
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.